Haiyun Xie

Haiyun Xie

Auto-generated profile, based on publicly available information

Haiyun Xie

Department of Urology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, PR China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
HXHaiyun Xie
Haiyun Xie
JLJiangfeng Li
Jiangfeng Li
YYYufan Ying
Yufan Ying
HYHuaqing Yan
Huaqing Yan
KJKe Jin
Ke Jin
LXLiping Xie
Liping Xie
N6‐Methyladenosine (m 6 A) modification, the most prevalent modification of eukaryotic messenger RNA (mRNA), is involved in the progression of various tumours. However, the specific role of m 6 A in bladder cancer (BCa) is still poorly understood. In this study, we demonstrated the tumour‐promoting function and specific regulatory mechanism of m 6 A axis, consisting of the core ‘writer’ protein METTL3 and the major reader protein YTHDF2. Depletion of METTL3 impaired cancer proliferation and cancer metastasis in vitro and in vivo. Through transcriptome sequencing, m 6 A methylated RNA immunoprecipitation (MeRIP) and RIP, we determined that the METTL3/YTHDF2 m 6 A axis directly degraded the mRNAs of the tumour suppressors SETD7 and KLF4, contributing to the progression of BCa. In addition, overexpression of SETD7 and KLF4 revealed a phenotype consistent with that induced by depletion of the m 6 A axis. Thus, our findings on the METTL3/YTHDF2/SETD7/KLF4 m 6 A axis provide the insight into the underlying mechanism of carcinogenesis and highlight potential therapeutic targets for BCa.

17 October 2022 in International Journal of Biological Sciences
Verified
Journal Article
Open access
PDF file
WLWenqin Luo
Wenqin Luo
HWHuan Wang
Huan Wang
LRLiangliang Ren
Liangliang Ren
ZLZeyi Lu
Zeyi Lu
QZQiming Zheng
Qiming Zheng
GLGonghui Li
Gonghui Li
A lipid droplet (LD) is an organelle that consists of a phospholipid monolayer and a neutral lipid core, with proteins embedded in or attached to its surface. Until recently, cancers had long been regarded as genetic disorders with the abnormal activation of oncogenes and inactivation of tumor suppressor genes before their quality of a metabolic disorder began to be recognized. The last decade has witnessed the recognition of several metabolic characteristics of cancer cells, among which one is the accumulation of lipid droplets; therefore, attention has been given to exploring the role of LDs in carcinomas. In addition, there has been a remarkable expansion in understanding the complexity of LD's function in cellular homeostasis, including but not limited to energy supply, endoplasmic reticulum (ER) stress and oxidative stress management, or lipotoxicity alleviation. Thus, lipid droplet-associated proteins, which to a great extent determine the dynamics of a lipid droplet, have attracted the interest of numerous cancer researchers and their potential as cancer diagnostic biomarkers and therapeutic targets has been affirmed by emerging evidence. In this review, we systematically summarize the critical role of LDs in cancer and then focus on four categories of lipid droplet-associated proteins having the most direct influence on LD biosynthesis (diacylglycerol acyltransferase 1 (DGAT1) and diacylglycerol acyltransferase 2 (DGAT2)), degradation (adipose triglyceride lipase (ATGL)), and two renowned protein families on the LD surface (perilipins and cell death-inducing DNA fragmentation factor alpha-like effectors (CIDEs)). In this way, we aim to highlight their important role in tumor progression and their potential in clinical applications.

17 November 2022 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
HXHaiyun Xie
Haiyun Xie
MWMingchao Wang
Mingchao Wang
HYHaifeng Yu
Haifeng Yu
HWHuan Wang
Huan Wang
LDLifeng Ding
Lifeng Ding
GLGonghui Li
Gonghui Li
7-methylguanosine (m7G) modification is recently found to conservatively exist in RNA internal position besides mRNA caps and mediates the various RNA metabolisms. As the core confirmed transmethylase of m7G modification, METTL1 has been reported in certain human cancers. However, the role of internal m7G at miRNAs and its core writer METTL1 in bladder cancer (BCa) remains to be elucidated. Here, we demonstrated that METTL1 was indispensable for BCa proliferation and metastasis in vitro and in vivo. By combining miRNA sequencing, m7G methylated RNA immunoprecipitation (MeRIP) and RIP, we identified METTL1 promoted the processing of miR-760 in an m7G-dependent manner. Transcription sequencing suggested that METTL1 indirectly degrades tumor suppressor ATF3 mRNA mediated by miR-760. Together, we concluded a regulatory axis composed of METTL1/m7G/miR-760/ATF3 in regulating BCa progression and provided potential therapeutic targets for BCa.

17 August 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
XWXiao Wang
Xiao Wang
HXHaiyun Xie
Haiyun Xie
YYYufan Ying
Yufan Ying
DCDanni Chen
Danni Chen
JLJiangfeng Li
Jiangfeng Li
Epigenetics has long been a hot topic in the field of scientific research. The scope of epigenetics usually includes chromatin remodelling, DNA methylation, histone modifications, non‐coding RNAs and RNA modifications. In recent years, RNA modifications have emerged as important regulators in a variety of physiological processes and in disease progression, especially in human cancers. Among the various RNA modifications, m6A is the most common. The function of m6A modifications is mainly regulated by 3 types of proteins: m6A methyltransferases (writers), m6A demethylases (erasers) and m6A‐binding proteins (readers). In this review, we focus on RNA m6A modification and its relationship with urological cancers, particularly focusing on its roles and potential clinical applications.